Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (43)
Guidance programme
(
1 selected
)
Guidance programme
NICE guidelines (1)
Technology appraisal guidance (43)
Apply filters
Showing 21 to 30 of 43
Sort by
Title
Date
Apply sorting
lung cancer
Remove lung cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell
lung cancer
[ID6248]
Technology appraisal guidance
TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell
lung cancer
after complete tumour resection (Review of TA761) [ID5120]
Technology appraisal guidance
14 August 2024
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell
lung cancer
[ID6328]
Technology appraisal guidance
TBC
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell
lung cancer
[ID5094]
Technology appraisal guidance
16 October 2024
Pembrolizumab for adjuvant treatment of resected non-small-cell
lung cancer
[ID3907]
Technology appraisal guidance
16 October 2024
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell
lung cancer
[ID3861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell
lung cancer
after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell
lung cancer
[ID4006]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell
lung cancer
after pembrolizumab with platinum-based chemotherapy [ID4028]
Technology appraisal guidance
TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell
lung cancer
[ID3873]
Technology appraisal guidance
TBC
Previous page
1
2
Current page
3
4
5
Page
3
of
5
Next page
Results per page
10
25
50
All
Back to top